JPWO2020086937A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020086937A5 JPWO2020086937A5 JP2021522334A JP2021522334A JPWO2020086937A5 JP WO2020086937 A5 JPWO2020086937 A5 JP WO2020086937A5 JP 2021522334 A JP2021522334 A JP 2021522334A JP 2021522334 A JP2021522334 A JP 2021522334A JP WO2020086937 A5 JPWO2020086937 A5 JP WO2020086937A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- enzyme
- cgl enzyme
- isolated
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 claims 46
- 108090000790 Enzymes Proteins 0.000 claims 46
- 239000000203 mixture Substances 0.000 claims 18
- 239000004474 valine Substances 0.000 claims 14
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 14
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 claims 12
- 239000004471 Glycine Substances 0.000 claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 9
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 9
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 229960003067 Cystine Drugs 0.000 claims 7
- 206010011778 Cystinuria Diseases 0.000 claims 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 102200026577 CYP2D6 L91M Human genes 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 5
- 229960005261 Aspartic Acid Drugs 0.000 claims 4
- 229960002433 Cysteine Drugs 0.000 claims 4
- 229960002989 Glutamic Acid Drugs 0.000 claims 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 4
- 102000028624 Cystathionine gamma-Lyase Human genes 0.000 claims 3
- 108010045283 Cystathionine gamma-Lyase Proteins 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 241000282405 Pongo abelii Species 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- 230000037213 diet Effects 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 102100001249 ALB Human genes 0.000 claims 2
- 101710027066 ALB Proteins 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 210000003734 Kidney Anatomy 0.000 claims 2
- 235000013878 L-cysteine Nutrition 0.000 claims 2
- 239000004201 L-cysteine Substances 0.000 claims 2
- 235000019393 L-cystine Nutrition 0.000 claims 2
- 239000004158 L-cystine Substances 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 241000282576 Pan paniscus Species 0.000 claims 2
- 241000282577 Pan troglodytes Species 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- GKZARTFJSANTLY-UHFFFAOYSA-N Sumatriptan Chemical class [CH]1C(CS(=O)(=O)NC)=CC=C2N=CC(CCN(C)C)=C21 GKZARTFJSANTLY-UHFFFAOYSA-N 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 150000004676 glycans Polymers 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 229920001427 mPEG Polymers 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims 1
- 108010058907 Tiopronin Proteins 0.000 claims 1
- 210000001635 Urinary Tract Anatomy 0.000 claims 1
- 210000002700 Urine Anatomy 0.000 claims 1
- 102200054269 VLDLR V59I Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000001580 bacterial Effects 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004962 mammalian cells Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- -1 succinimidyl carboxymethyl ester Chemical class 0.000 claims 1
- 229960004402 tiopronin Drugs 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751197P | 2018-10-26 | 2018-10-26 | |
| US62/751,197 | 2018-10-26 | ||
| PCT/US2019/058021 WO2020086937A1 (fr) | 2018-10-26 | 2019-10-25 | Enzymes de dégradation de cystine/cystéine de primates biotechnologiques pour des utilisations thérapeutiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505689A JP2022505689A (ja) | 2022-01-14 |
| JPWO2020086937A5 true JPWO2020086937A5 (fr) | 2022-08-15 |
Family
ID=70331739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522334A Pending JP2022505689A (ja) | 2018-10-26 | 2019-10-25 | 治療的使用のための、遺伝子操作された霊長類シスチン／システイン分解酵素 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210380962A1 (fr) |
| EP (1) | EP3870081A4 (fr) |
| JP (1) | JP2022505689A (fr) |
| KR (1) | KR20210084539A (fr) |
| CN (1) | CN113260324A (fr) |
| AR (1) | AR116866A1 (fr) |
| AU (1) | AU2019363606A1 (fr) |
| BR (1) | BR112021007687A2 (fr) |
| CA (1) | CA3117046A1 (fr) |
| CO (1) | CO2021006432A2 (fr) |
| IL (1) | IL282626A (fr) |
| MX (1) | MX2021004754A (fr) |
| SG (1) | SG11202104205XA (fr) |
| TW (1) | TW202029967A (fr) |
| WO (1) | WO2020086937A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060275279A1 (en) * | 2005-06-06 | 2006-12-07 | Rozzell J D | Methods for dissolving cystine stones and reducing cystine in urine |
| US8709407B2 (en) * | 2010-02-04 | 2014-04-29 | Aemase, Inc. | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof |
| ES2745287T3 (es) * | 2013-08-29 | 2020-02-28 | Univ Texas | Enzimas degradadoras de cistina/cisteína de primate genomanipuladas como agentes antineogénicos |
| CN105531371B (zh) * | 2013-08-29 | 2021-04-09 | 得克萨斯大学体系董事会 | 用于治疗目的的工程改造的灵长类动物l-甲硫氨酸酶 |
| EP3187190A1 (fr) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine |
| WO2018209211A1 (fr) * | 2017-05-12 | 2018-11-15 | Board Of Regents, The University Of Texas System | Enzymes de dégradation de cystine/cystéine de primates à modification biotechnologique pour utilisations thérapeutiques |
| IL270503B1 (en) * | 2017-05-12 | 2024-06-01 | Univ Texas | Depletion of homocysteine by human enzymes for the treatment of patients with hyperhomocysteinemia and homocystinuria |
-
2019
- 2019-10-25 KR KR1020217015692A patent/KR20210084539A/ko unknown
- 2019-10-25 WO PCT/US2019/058021 patent/WO2020086937A1/fr active Application Filing
- 2019-10-25 BR BR112021007687-5A patent/BR112021007687A2/pt unknown
- 2019-10-25 SG SG11202104205XA patent/SG11202104205XA/en unknown
- 2019-10-25 EP EP19874951.7A patent/EP3870081A4/fr active Pending
- 2019-10-25 JP JP2021522334A patent/JP2022505689A/ja active Pending
- 2019-10-25 TW TW108138620A patent/TW202029967A/zh unknown
- 2019-10-25 US US17/288,151 patent/US20210380962A1/en active Pending
- 2019-10-25 AR ARP190103101A patent/AR116866A1/es unknown
- 2019-10-25 AU AU2019363606A patent/AU2019363606A1/en not_active Abandoned
- 2019-10-25 CA CA3117046A patent/CA3117046A1/fr active Pending
- 2019-10-25 CN CN201980079530.0A patent/CN113260324A/zh active Pending
- 2019-10-25 MX MX2021004754A patent/MX2021004754A/es unknown
-
2021
- 2021-04-25 IL IL282626A patent/IL282626A/en unknown
- 2021-05-18 CO CONC2021/0006432A patent/CO2021006432A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2280083T3 (es) | Composiciones de proteinas de fusion ob y metodos. | |
| JP5721954B2 (ja) | 尿酸オキシダーゼ | |
| US8178334B2 (en) | Variant form of urate oxidase and use thereof | |
| ES2856881T3 (es) | Formas variantes de urato oxidasa y su uso | |
| EP0816381B1 (fr) | Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol | |
| TW200914617A (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| CA2786090A1 (fr) | Analogues d'interferons | |
| JP2020519278A5 (fr) | ||
| US20060105948A1 (en) | GLP-2 derivatives | |
| ES2228082T3 (es) | Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados. | |
| JPWO2020086937A5 (fr) | ||
| Zhang et al. | Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats | |
| RU2021114677A (ru) | Модифицированные способами инженерии ферменты приматов, деградирующие цистин/цистеин, для терапевтических применений | |
| Lollo et al. | Gene therapy strategies for the treatment of chronic viral hepatitis | |
| JP2916947B2 (ja) | Ｃｐｂ―ｉの安定化方法及び製剤組成物 | |
| Chiang et al. | Contribution of poly (amino acids) to advances in pharmaceutical biotechnology | |
| WO2001052901A1 (fr) | Medicaments pour la therapie genique | |
| JP2916948B2 (ja) | Ｃｐｂ―ｉの安定化方法及びこの製剤組成物 | |
| Shin et al. | Conjugation of succinylated gelatin to soybean trypsin inhibitor | |
| Hoffman | PEG-methioninase | |
| WO2023220501A1 (fr) | Peptides thérapeutiques activables et leurs utilisations | |
| RU2021105703A (ru) | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение | |
| AU2011257764A1 (en) | A variant form of urate oxidase and use thereof | |
| NAYAK | International Journal of Pharmacy and Pharmaceutical Sciences | |
| CN101883781A (zh) | 7p及其衍生肽和其应用 |